Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO Brings Lawton In-House As VP-Reg Affairs/Counsel: PDUFA III Looms

Executive Summary

Biotechnology Industry Organization VP-Regulatory Affairs Stephan Lawton will focus on the reauthorization of the Prescription Drug User Fee Act upon joining the association on Jan. 1, 2001.

You may also be interested in...



BIO Seeking Regulatory Affairs Head, Gets Friendly Face In House Committee

The Biotechnology Industry Organization is conducting a search for a new vice president of regulatory affairs

BIO Seeking Regulatory Affairs Head, Gets Friendly Face In House Committee

The Biotechnology Industry Organization is conducting a search for a new vice president of regulatory affairs

BIO VP-Health Policy Cohen Joins From HIAA To Handle Medicare Rx Policy

The Biotechnology Industry Organization is gearing up for a more active role in the Medicare Rx debate in 2001 by recruiting HIAA chief lobbyist Sharon Cohen to serve as VP-health policy.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel